<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="2088">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 08, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04597047</url>
  </required_header>
  <id_info>
    <org_study_id>S-CLIN-PROT-0031</org_study_id>
    <nct_id>NCT04597047</nct_id>
  </id_info>
  <brief_title>Research &amp; Evaluation of LumiraDx SARS-CoV-2 (COVID-19) Point of Care Ab Test</brief_title>
  <acronym>CAPTURE-2</acronym>
  <official_title>A Multicenter Covid-19 Study Conducted to Evaluate the Agreement Between Fingerstick Whole Blood, Venous Whole Blood, Plasma &amp; Serum as Determined on the LumiraDx POC SARS-CoV-2 Ab Test &amp; to Evaluate the Ease of Use at Point of Care Sites</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>LumiraDx UK Limited</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>LumiraDx UK Limited</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_unapproved_device>Yes</is_unapproved_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Evaluation of the agreement between fingerstick samples, venous blood, serum and plasma&#xD;
      samples when using the LumiraDx SARS-CoV-2 Ab Test against the reference method, using&#xD;
      standard qualitative comparison techniques.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a prospective, multi-centre study. One (1) Reference Lab and approximately six (6)&#xD;
      Healthcare or Research Facilities within geographic areas experiencing current Covid-19&#xD;
      outbreaks in the U.S. will participate in the study. Study sites may be Point of Care (POC)&#xD;
      locations, such as physician office laboratories, urgent care and outpatient clinics, or&#xD;
      dedicated research sites.&#xD;
&#xD;
      A subject's participation in this study will consist of a single visit. Following completion&#xD;
      of the informed consent process and a review of Inclusion/Exclusion criteria to determine&#xD;
      eligibility, each subject will receive a unique study identification number.&#xD;
&#xD;
      Subjects will undergo two (2) fingerstick lancing's and 1 (one) venous blood draw. A total of&#xD;
      eleven (11) tests (LumiraDx SARS-CoV-2 Ab and haematocrit) will then be performed using these&#xD;
      samples. Specimens will be obtained from each subject enrolled using standard collection&#xD;
      methods.&#xD;
&#xD;
      All operators at a site level performing the LumiraDx SARS-CoV-2 Ab POC Test in this study&#xD;
      will be required to complete training detailing the running of the LumiraDx Test/Instrument.&#xD;
      This will be completed as part of a familiarization period and all operators will be required&#xD;
      to show proficiency in using the system for QC, fingerstick, whole blood, plasma and serum&#xD;
      testing prior to testing subjects. This will be captured on relevant training forms as part&#xD;
      of the site initiation visit. In addition, the operator's satisfaction and ease of use of the&#xD;
      LumiraDx SARS-CoV-2 Ab Test will be evaluated by completing an Intended Use Operator&#xD;
      Questionnaire.&#xD;
&#xD;
      The LumiraDx SARS-CoV-2 Ab POC Testing will be performed at the site on the same day as the&#xD;
      date of collection. Samples will be shipped to a central laboratory for reference testing.&#xD;
      Testing in the reference laboratory will be performed by trained laboratory personnel.&#xD;
&#xD;
      Approximately 200 subjects will be enrolled in this study. Approximately thirty (30)&#xD;
      SARS-CoV-2 positive, and thirty (30) samples negative for SARS-CoV-2 will be enrolled at each&#xD;
      site.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 20, 2020</start_date>
  <completion_date type="Anticipated">December 31, 2022</completion_date>
  <primary_completion_date type="Anticipated">October 31, 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>Participants are asked to provide Capillary and Venous Blood Samples.</intervention_model_description>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Performance Evaluation</measure>
    <time_frame>4 months</time_frame>
    <description>Evaluation of the agreement between fingerstick samples and venous blood samples on the device; and venous blood, serum and plasma samples on the device versus reference method, using standard qualitative comparison techniques.</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Covid19</condition>
  <arm_group>
    <arm_group_label>All Patients:</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Capillary and Venous Blood Collections</description>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Capillary Collection &amp; Testing</intervention_name>
    <description>Two (2) fingersticks will be performed on each subject and capillary blood tested in the LumiraDx SARS-CoV-2 Ab test</description>
    <arm_group_label>All Patients:</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Venous Draw &amp; Testing</intervention_name>
    <description>One (1) Venous Draw (to include one (1) 6.0 mL EDTA tube and one (1) 3.5 mL serum separator tube) will be collected from each subject. Blood will be tested in the LumiraDx SARS-CoV-2 Ab test</description>
    <arm_group_label>All Patients:</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Male and female subjects aged â‰¥ 2 years.&#xD;
&#xD;
          2. The subject must have a documented SARS-CoV-2 PCR test in the past 7-30 days.&#xD;
             (subjects must be 14+ days post symptom onset at the time of recruitment).&#xD;
&#xD;
          3. Written informed consent must be obtained prior to study enrollment.&#xD;
&#xD;
               1. A subject who is 18 years or older must be willing to give written informed&#xD;
                  consent and must agree to comply with study procedures.&#xD;
&#xD;
               2. The Legal Guardian or Legal Authorized Representative of a subject who is under&#xD;
                  the age of 18 must give written informed consent and agree to comply with study&#xD;
                  procedures. Active written assent should be obtained from children of appropriate&#xD;
                  intellectual age (as defined by the IRB).&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Skin lesions or conditions that would preclude a fingerstick and or a venous blood&#xD;
             draw.&#xD;
&#xD;
          2. The subject is currently receiving or has received within the past thirty (30) days of&#xD;
             the study visit an experimental biologic, drug, or device including either treatment&#xD;
             or therapy.&#xD;
&#xD;
          3. The subject has previously participated in this research study.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>2 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Vicki Kalen</last_name>
    <role>Principal Investigator</role>
    <affiliation>Eclipse Clinical Research</affiliation>
  </overall_official>
  <overall_official>
    <last_name>William Simon</last_name>
    <role>Principal Investigator</role>
    <affiliation>Professional Research Network of Kansas</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Matthew Morgan</last_name>
    <role>Principal Investigator</role>
    <affiliation>Centura Health Physician Group</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Melanie Hoppers</last_name>
    <role>Principal Investigator</role>
    <affiliation>Physicians Quality Care of Jackson</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>David Craig</last_name>
    <phone>+4401786533232</phone>
    <email>david.craig@lumiradx.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Eclipse Clinical Research</name>
      <address>
        <city>Tucson</city>
        <state>Arizona</state>
        <zip>85745</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>David Craig</last_name>
      <email>david.craig@lumiradx.com</email>
    </contact>
    <investigator>
      <last_name>Vicki Kalen</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centura Health Physician Group, Northglenn Office</name>
      <address>
        <city>Northglenn</city>
        <state>Colorado</state>
        <zip>80234</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>David Craig</last_name>
    </contact>
    <contact_backup>
      <email>david.craig@lumiradx.com</email>
    </contact_backup>
    <investigator>
      <last_name>Matthew Morgan</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Professional Research Network of Kansas</name>
      <address>
        <city>Wichita</city>
        <state>Kansas</state>
        <zip>67203</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>David Craig</last_name>
      <email>david.craig@lumiradx.com</email>
    </contact>
    <investigator>
      <last_name>William Simon</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Physicians Quality Care of Jackson</name>
      <address>
        <city>Jackson</city>
        <state>Tennessee</state>
        <zip>38305</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>David Craig</last_name>
      <email>david.craig@lumiradx.com</email>
    </contact>
    <investigator>
      <last_name>Melanie Hoppers</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2020</verification_date>
  <study_first_submitted>October 19, 2020</study_first_submitted>
  <study_first_submitted_qc>October 20, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">October 22, 2020</study_first_posted>
  <last_update_submitted>October 20, 2020</last_update_submitted>
  <last_update_submitted_qc>October 20, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">October 22, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>POC</keyword>
  <keyword>SARS-CoV-2</keyword>
  <keyword>Antibody</keyword>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

